Les publications

Retrouvez ici les publications des équipes de recherche du CGO. Page en cours de mise à jour...

338 publications
Année de publication :
Réseaux :

Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from…

Eculizumab is an anti-C5 monoclonal antibody approved for rare diseases including atypical haemolytic-uraemic syndrome. The maintenance phase dosing regimen is identical for all adult patients: 1200 mg every 2 weeks.

  • Ref: Br J Clin Pharmacol. 2020 Oct 28.
  • Auteurs : Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Contin-Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P. Br
Lire la publication

Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.

Drug repurposing has lately received increasing interest in several diseases especially in cancers, due to its advantages in facilitating the development of new therapeutic strategies, by adopting a cost-friendly approach and avoiding the strict Food and Drug Administration (FDA) regulations.

  • Ref: Curr Med Chem. 2020 Sep 8.
  • Auteurs : Nehme R, Hallal R, El Dor M, Kobeissy F, Gouilleux F, Mazurier F, Zibara K.
Lire la publication

ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.

Multiple myeloma (MM) is a plasma cell neoplasm that remains incurable due to innate or acquired resistance. Although MM cells produce high intracellular levels of reactive oxygen species (ROS), we hypothesised that they could remain sensitive to ROS unbalance.

  • Ref: Cells. 2020 Oct 26;9(11):E2357.
  • Auteurs : Caillot M, Zylbersztejn F, Maitre E, Bourgeais J, Hérault O, Sola B.
Lire la publication